Rituximab and abatacept for rheumatoid arthritis.
Estimates from the UK indicate that around 0.5-1.0% of the population have rheumatoid arthritis. Here we assess the place of rituximab (MabThera--Roche Products Ltd) and abatacept (Orencia--Bristol-Myers-Squibb), drugs in two new classes, which are licensed for certain adults with the condition.